ArticleMolecular pharmacology2017
Structural Insights into the Atomistic Mechanisms of Action of Small Molecule Inhibitors Targeting the KCa3.1 Channel Pore.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 49 citations in OpenAlex.
- Mutation-Induced Pocket Deactivation: How Ser353/Pro245 Alters KArchiv der Pharmazie · 2026Article
- Senicapoc in Patients with Idiopathic Pulmonary Fibrosis or Other Progressive Fibrotic Interstitial Lung Diseases: Protocol for a Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Trial.Diagnostics (Basel, Switzerland) · 2026Article
- Skin capillary endothelial cells form a network of spatiotemporally conserved CabioRxiv : the preprint server for biology · 2026Article
- Visualization of KACS pharmacology & translational science · 2025Article
- Design and structural basis of selective 1,4-dihydropyridine inhibitors of the calcium-activated potassium channel KProceedings of the National Academy of Sciences of the United States of America · 2025Article
- 6,7-Dichloro-1H-indole-2,3-dione-3-oxime functions as a superagonist for the intermediate-conductance CaMolecular pharmacology · 2025Article
- Fluorescent Probes to Image the KPharmaceutics · 2025Article
- Harnessing Deep Learning Methods for Voltage-Gated Ion Channel Drug Discovery.Physiology (Bethesda, Md.) · 2025Review
- Repurposing the KTranslational stroke research · 2024Article
- Toward high-resolution modeling of small molecule-ion channel interactions.Frontiers in pharmacology · 2024Article
- Gating kinetics and pharmacological properties of small-conductance CaBiophysical journal · 2023Article
- Single amino acid residue mediates reciprocal specificity in two mosquito odorant receptors.eLife · 2022Article
- The erythroid K-Cl cotransport inhibitor [(dihydroindenyl)oxy]acetic acid blocks erythroid CaAmerican journal of physiology. Cell physiology · 2022Article
- Dextran sodium sulfate potentiates NLRP3 inflammasome activation by modulating the KCa3.1 potassium channel in a mouse model of colitis.Cellular & molecular immunology · 2022Article
- Pose Classification Using Three-Dimensional Atomic Structure-Based Neural Networks Applied to Ion Channel-Ligand Docking.Journal of chemical information and modeling · 2022Review
- TRPM2 Oxidation Activates Two Distinct Potassium Channels in Melanoma Cells through Intracellular Calcium Increase.International journal of molecular sciences · 2021Article
- Identification of the Functional Binding Site for the Convulsant Tetramethylenedisulfotetramine in the Pore of theMolecular pharmacology · 2021Article
- Comparison of the pharmacological profiles of arginine vasopressin and oxytocin analogs at marmoset, macaque, and human vasopressin 1a receptor.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2020Article
- Synthesis of Small-Molecule Fluorescent Probes for the In Vitro Imaging of Calcium-Activated Potassium Channel KAngewandte Chemie (International ed. in English) · 2020Article
- Suppression of CaEMBO reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Hai M NguyenDepartment of Pharmacology (H.M.N, V.S., B.P., D.P.J., H.W.) and Department of Physiology and Membrane Biology (V. Y.-Y.), School of Medicine, University of California at Davis, Davis, California.
Vikrant SinghDepartment of Pharmacology (H.M.N, V.S., B.P., D.P.J., H.W.) and Department of Physiology and Membrane Biology (V. Y.-Y.), School of Medicine, University of California at Davis, Davis, California.
Brandon PresslyDepartment of Pharmacology (H.M.N, V.S., B.P., D.P.J., H.W.) and Department of Physiology and Membrane Biology (V. Y.-Y.), School of Medicine, University of California at Davis, Davis, California.
David Paul JenkinsDepartment of Pharmacology (H.M.N, V.S., B.P., D.P.J., H.W.) and Department of Physiology and Membrane Biology (V. Y.-Y.), School of Medicine, University of California at Davis, Davis, California.
Heike WulffDepartment of Pharmacology (H.M.N, V.S., B.P., D.P.J., H.W.) and Department of Physiology and Membrane Biology (V. Y.-Y.), School of Medicine, University of California at Davis, Davis, California yarovoy@ucdavis.edu hwulff@ucdavis.edu.
Vladimir Yarov-YarovoyDepartment of Pharmacology (H.M.N, V.S., B.P., D.P.J., H.W.) and Department of Physiology and Membrane Biology (V. Y.-Y.), School of Medicine, University of California at Davis, Davis, California yarovoy@ucdavis.edu hwulff@ucdavis.edu.
University of California, Davis · US
Funding
Training and Education CoreU54NS079202 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LEIN, PAMELA J · 2012 to 2021
$35.7MPredoctoral Training in Pharmacological SciencesT32GM099608 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HELL, JOHANNES W · 2012 to 2021
$2.2MNIGMS NIH HHS T32 GM099608NINDS NIH HHS U54 NS079202
Abstract
The intermediate-conductance Ca
Indexed as
Models, MolecularAmino Acid SequenceBinding SitesHumansIntermediate-Conductance Calcium-Activated Potassium ChannelsLigandsMolecular Docking SimulationNifedipinePotassium Channel BlockersProtein DomainsSequence AlignmentSmall Molecule LibrariesStructural Homology, ProteinStructure-Activity RelationshipThiazines4-((3-(trifluoromethyl)phenyl)methyl)-2H-1,4-benzothiazin-3(4H)-oneIntermediate-Conductance Calcium-Activated Potassium ChannelsKCNN4 protein, humanLigandsNifedipinePotassium Channel BlockersSmall Molecule LibrariesThiazines
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.